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treatment failure. Times to treatment failure, during a speciﬁed
observation period, were compared using an adjusted Cox
model. Drug consumption, clinic visits and glaucoma procedures
during the period were subjected to a cost minimization analy-
sis, adopting the NHS perspective. Results: Out of 56,612
patients elicited, 39,808 received at least one topical prescription
for glaucoma. Amongst these, 1164 were prescribed a β-
blocker+alpha-2 agonist and 5581 a β-blocker+CAI, in place of
failed treatments for glaucoma. No signiﬁcant demographic dif-
ferences were observed between groups. The mean age was 68.1
years and 51.9% were female. By the end of one year 69.7% of
patients failed to respond to β-blocker+alpha-2 as did 59.5% to
β-blocker+CAI (p < 0.001). The hazard ratio (0.818) for failure
was less for β-blocker+CAI (p < 0.001) than β-blocker+alpha-2,
after adjusting on age, gender, and comorbidities. Adjusted costs
of β-blocker+alpha-2 regimens were estimated at £357 p.a. and
were not statistically different (p = 0.61) from β-blocker+CAI
regimens (£348 p.a.). CONCLUSION: According to UK-GPRD
information, beta-blocker + CAI is more efﬁcient than beta-
blocker + alpha-2 in replacing failed treatments for glaucoma.
Patients continued longer with â blocker+CAI treatment than
beta-blocker + alpha-2, at a similar cost.
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OBJECTIVES: To compare the effectiveness and associated costs
of Travatan (prostaglandin) and Xalacom (prostaglandin + â-
blocker) as ﬁrst-line treatments for glaucoma, according to the
UK General Practitioner Research Database (UK-GPRD).
METHODS: Patients diagnosed with ocular hypertension or
glaucoma treated with a topical treatment, surgery or by laser
were identiﬁed. Patients conﬁrmed to have been prescribed ﬁrst
line Travatan or Xalacom monotherapy were selected. Treatment
failure was deﬁned as a prescription change (adding or remov-
ing a topical treatment). Time to treatment failure was compared
using an adjusted Cox model. Drugs, visits and glaucoma pro-
cedures consumed during a speciﬁed one-year period were
entered into a cost minimization analysis, viewed from a NHS
perspective. Results: 56,612 patients were identiﬁed and 39,808
had received at least one topical prescription for glaucoma; 176
received Xalacom and 639 got Travatan as ﬁrst-line treatments
for glaucoma. No signiﬁcant difference was found between the
characteristics of the two patient groups. Patients were 70.2
years old at diagnosis, on average, and 48.2% were male. At one
year, 35.8% of the patients failed with Xalacom, and 27.1%
failed with Travatan (p = 0.024). The hazard ratio for treatment
failure was 0.749 and less with Travatan (p = 0.04) than with
Xalacom, after adjusting for age, gender, and comorbidities.
Xalacom regimens were statistically (p < 0.001) more costly
(£328 p.a.) than Travatan regimens (£216 p.a.). CONCLU-
SION: According to UK-GPRD information, Travatan domi-
nated Xalacom as ﬁrst-line treatment for glaucoma patients.
Patients remained under Travatan treatment longer and at a
lower cost.
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OBJECTIVES: To determine the cost of blindness in the Czech
Republic. METHODS: Determination of cost is based on the
search of public database in 2006. Cost are calculated from the
state perspective, cost from the private sector are not included
(foundation, donation etc.). Analysis include direct cost: sup-
portive equipment, counseling, home care, co-morbidity treat-
ment, rehabilitation, retraining, social home for blind people,
social beneﬁts—allowance, community care and indirect cost:
productivity lost which was calculated via human capital
method. Three cost categories were selected to describe cost of
blindness: 1.) Blind in productive age, 2.) Blind in retirement
living at home, 3.) Blind in retirement placed in social home for
blind people. Costs in each group were divided in cost ﬁrst year
and following years. RESULTS: The cost is highest ﬁrst year in
group 1) blind in productive age and reach 733,000 CZK (app.
34,900 USD) per year. Following years is the cost lower 522,000
CZK (app. 24,900 USD) in this group. The second group which
includes blind people placed at home utilize 408,000 CZK (app.
19,400 USD) during ﬁrst year and 197,000 CZK following years
(9400 USD). The cost of third group which includes patients
living at social home was 324,000 CZK (15,400 USD) both ﬁrst
and following years. CONCLUSION: Cost of blindness from
ranges from 197,000 CZK to 733,000 CZK (app. 9400 to
34,900 USD) per year in the Czech Republic. Cost of blindness
represents a substantial burden for Czech state and society.
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OBJECTIVES: Develop a health economic model to measure the
standard of care costs associated with progression of primary
open angle glaucoma. METHODS: We used Monte Carlo tech-
niques to model the cost of a simulated cohort of 600 patients
with Mean Deviation (MD) score progression over four years.
MD scores were used to estimate resource utilization for the
cohort using regression equations from an analysis of the rela-
tionship between resources and MD score in the worst eye from
a U.S. chart review of glaucoma patients (N = 161, mean age
66.3, minimum follow-up of four years). Both medical (number
of ofﬁce visits, visual ﬁeld exams, trabeculoplasties and tra-
beculectomies) and pharmacy resources (number of glaucoma
medications) were included in the model. Unit costs were applied
to the resource utilization estimates. MD scores were also used
to predict utility scores based on a regression analysis of utility
scores among glaucoma patients; the quality-adjusted-life years
(QALYs) over four years was modeled. RESULTS: The four-year
cost for the cohort was $3957 per patient ($598 in pharmacy
costs and $3359 in medical costs) with 2.96 QALYs accumulated
over 4 years. CONCLUSION: Glaucoma progression as evi-
denced by worsening MD scores is associated with a loss in
quality of life and substantial costs over four years of follow-up.
Advances in understanding the economic burden of glaucoma
progression may help to guide strategies for preventing and
delaying onset of this disease and lead to cost savings by slowing
disease progression.
